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Incident acute coronary syndromes in chronic dialysis patients Chronic dialysis patients have a greatly increased age-
in the United States. adjusted incidence and prevalence of coronary heart dis-
Background. Patients on dialysis have a disproportionately ease [1] as well as increased mortality after myocardial
high rate of cardiovascular disease (CVD). However, the inci-
infarction [2] compared to the general population. Clini-dence and risk factors for incident acute coronary syndromes
cal correlates have been described for patients for coro-(ACS) have not been previously assessed in dialysis patients.
nary heart disease at presentation to end-stage renalMethods. We analyzed the United States Renal Data System
(USRDS) Dialysis Morbidity and Mortality Study (DMMS) disease (ESRD) [3]. Risk factors for incident acute coro-
Wave II in a historical cohort study of ACS. Data from 3374 nary syndromes (ACS) thus far have been reported only
patients who started dialysis in 1996 with valid follow-up times for renal transplant recipients [4] and diabetic patientswere available for analysis, censored at the time of renal trans-
on the renal transplant waiting list, which found thatplantation and followed until March 2000. Cox regression anal-
renal transplantation was independently associated withysis was used to model factors associated with time to first
hospitalization for ACS (ICD9 code 410.x or 411.x) adjusted for a lower rate of ACS [5]. Both of these studies found that
comorbidities, demographic factors, baseline laboratory values, male gender and older age were associated with a higher
blood pressures and cholesterol levels, type of vascular access, rate of ACS. Rigatto et al found that elevated diastolic
dialysis adequacy, and cardioprotective medications (angio-
blood pressure, but not cholesterol, was associated withtensin-converting enzyme inhibitors, calcium channel blockers,
ischemic heart disease in renal transplant recipients [4].HMG-CoA reductase inhibitors (statins), beta blockers, and
Previous investigators have reported a link between cal-aspirin). Follow-up was 2.19  1.14 years.
Results. The incidence of ACS was 29/1000 person-years. Fac- cium, phosphorous, and parathyroid hormone levels and
tors associated with ACS were older age, the extreme high cardiac related death in a cohort of chronic dialysis pa-
and low ranges of serum cholesterol level, history of coronary tients [6], but the effects of cholesterol and blood pres-heart disease (CHD), male gender, and diabetes. No cardiopro-
sure, considered risk factors for coronary heart disease intective medications including statins had a significant associa-
the general population [7] and in renal transplant recipi-tion with ACS in this study. However, medications known to
reduce mortality after ACS were used in less than 50% of ents [4] were not assessed. Previous studies also did not
patients with known CHD at the start of the study, and statins assess for the effects of cardioprotective medications on
were used in less than 10% of patients with CHD. ACS in dialysis patients. We therefore performed an
Conclusions. Dialysis patients had similar risk factors for historical cohort study of the United States Renal DataACS compared to the general population. Cardioprotective med-
System (USRDS) DMMS Wave 2, which includes infor-ications were not associated with a significant benefit, possibly
mation on blood pressure, lipids, medications, and otherdue to their striking underutilization in this at-risk population.
important clinical data. Our objectives were to determine
the incidence and risk factors for incident hospitaliza-1The opinions are solely those of the authors and do not represent an
tions for acute coronary syndromes (primary hospitaliza-endorsement by the Department of Defense or the National Institutes
of Health. This is a U.S. Government work. There are no restrictions tion discharge ICD9 code 410.x, acute myocardial in-
on its use. farction, or 411.x, unstable angina) occurring after the
initiation of dialysis but prior to receipt of renal trans-Key words: cholesterol, angiotensin-converting enzyme inhibitors, beta
plantation.blockers, aspirin, HMG-CoA reductase inhibitors, calcium channel
blockers, USRDS, age, phosphorous, calcium, parathyroid hormone,
blood pressure.
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USRDS are described elsewhere [8]. Briefly, the USRDS from previous investigations using DMMS Wave 2 [12].
Because the short follow-up of the study would magnifycollects demographic and clinical data on patients who
have survived more than 90 days on dialysis. DMMS differences in the starting date of the study, and because
only a small proportion of study patients started dialysisWave 2 was a prospective cohort study that included all
eligible patients initiating peritoneal dialysis and a 20% in 1997, we restricted analysis to patients who started
dialysis in 1996. In the present analysis, patients wererandom sample of patients initiating hemodialysis in
1996 and early 1997. Other details of the demographics censored at the time of transplantation. Patients selected
to receive a renal transplant are generally healthier whenand extraction of DMMS 2 have been described in other
studies [9]. compared to typical dialysis patients; by excluding these
patients, our study results would only be applicable to
Data collection a less healthy group of individuals. However, because of
the known survival advantage of renal transplantationBaseline and follow-up data used in the study are
shown in Table 1. In addition, a maximum of 15 medica- [13], and the fact that valid comparisons of renal trans-
plantation only should be made with dialysis patients ontions prescribed to each patient at the study start date
(day 60 of dialysis) were recorded. From this list, the use the renal transplant waiting list [13], outcomes occurring
after renal transplantation were excluded, as per previ-of angiotensin-converting enzyme (ACE) inhibitors, beta
blockers (both selective and non-selective), calcium chan- ous investigators [14]. Although previous investigators
adjusted for changes in treatment modality during thenel blockers (subcategorized as dihyropyridine and non-
dihydropyridine), 3-hydroxy-3-methylglutaryl coenzyme follow-up period using time-dependent covariates, the re-
lationship between dialysis modality and mortality differsA (HMG-CoA) reductase inhibitors (statins), and aspi-
rin was determined. Carvedilol was approved for use by by duration of follow-up, and may not be as clinically
important as previously thought [15, 16]. Given the shortthe Federal Food and Drug Administration (FDA) in
February 1997, and therefore was not assessed. Because mean follow-up of the study, dialysis modality assignment
therefore was not changed even if patients later changedthere were many misspellings of medications in the data-
base, coding was determined by mutual agreement be- modalities, in an intention to treat fashion, also similar to
previous investigations [17]. We also used hemodialysistween two of the investigators (FCT and KCA). Assign-
ment of variables was necessarily subjective, but the access type [temporary, polytetrafluoroethylene (Gore-
Tex), fistula] in intention to treat fashion as covariatespresent analysis erred on the side of conservatism, not
assigning any entries to medication categories that could in analysis, since these might be associated with mortality
independently of dialysis modality. Twenty-four–hourbe construed as ambiguous by either of the investigators.
Triglycerides, low-density lipoprotein (LDL) and high- urine volumes were missing in 67% of patients, and thus
residual renal function was not calculated. Kt/V was calcu-density lipoprotein (HDL) values were missing in a large
percentage of patients and were not included in analysis. lated for hemodialysis patients according to the formula of
Daugirdas (KtV In (R 0.008 t) (4 3.5 R)Blood pressure levels, systolic (SBP) and diastolic (DBP),
were obtained as the mean of three readings before and 0.55 UF/V) [18]. Kt/V for peritoneal dialysis patients was
calculated according to current DOQI guidelines (http://after dialysis, respectively.
www.kidney.org/professionals/doqi/guidelines/doqiuppd_
Outcome measurements ii.html#5), using the Watson method for estimating total
body water. However, valid Kt/V could be calculatedSurvival status and cause of death were linked to the
DMMS Wave 2 data from the 2000 USRDS Patients for only 54% of peritoneal dialysis patients. Adequacy
was defined as a Kt/V 1.2 for hemodialysis patientsStandard Analysis File (SAF) via unique patient identi-
fiers assigned by the USRDS. The date and cause of and 2.0 for peritoneal dialysis patients.
death listed in a patient’s SAF was obtained from a form
Statistical analysissubmitted to the USRDS by the patient’s nephrologist
(form HCFA 2746). Patient survival status was complete Univariate analysis was performed with chi-square
testing for categorical variables and the Student t testthrough 31 March 2000. Hospitalization data for acute
coronary syndromes (ICD9 codes 410.x and 411.x) also for continuous variables. Variables with P value 0.1 in
univariate analysis were entered into the multivariatewere linked to the DMMS Wave 2 data as above, using
only the first hospitalization for a given patient during the models. Stepwise Cox proportional hazards model for
censored survival data was used to assess the associationstudy period. Hospitalizations for ACS were analyzed in
this fashion since all ACS, whether myocardial infarction between baseline factors and incident ACS, independent
of other predictors of survival. Kaplan-Meier plots wereor unstable angina, have a similar pathogenesis: rupture
of an atherosclerotic plaque with subsequent thrombosis inspected to verify the existence of proportional hazards.
Estimated hazard ratios (HR) along with correspondingand spasm [10, 11].
The present study methodology differed in three ways 95% confidence intervals (CI) and P values are reported
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Table 1. Factors assessed in ESRD patients
Univariate association with ACS
Factor P value Odds ratio 95% CI
N 3374
Factors significantly associated with ACS
Female 1572 (46.6) 0.001 0.60 0.44–0.8
African American 933 (27.7) 0.05 0.72 0.51–1.00
Mean age years 58.915.9 0.005 1.03 1.02–1.04
Ever transplanted yes/no 460 (13.6) 0.0001 0.18 0.08–0.40
Diabetes 1670 (50.7) 0.03 1.36 1.02–1.81
History of coronary heart disease 1091 (34.9) 0.001 4.28 3.15–5.81
History of congestive heart failure 1150 (36.2) 0.001 1.75 1.31–2.34
History of peripheral vascular disease 563 (17.9) 0.004 1.62 1.16–2.27
Cholesterol 159–192 mg/dL (2nd quartile vs. 4th) 0.01 2.02 1.18–3.49
Serum PTH 410 (4th quartile vs. 1st) 0.006 0.37 0.18–0.75
Aspirin yes 628 (18.6) 0.0001 2.85 2.13–3.82
Beta blockers yes 650 (19.3) 0.006 1.56 1.14–2.15
Selective 486 (14.4) 0.0001 1.94 1.39–2.71
Factors not significantly associated with ACS
Body mass index kg/m2 23.611.2
Stroke 336 (10.5)
Previous CABG 325 (9.6)
Previous PTCA 174 (5.2)
Previous coronary angiography 352 (10.4)
Malnutrition 446 (14.6)
LVH by EKG 479 (18.2)
LVH by ECHO 364 (16.5)
Cardiomegaly on CXR 888 (31)
EPO at day 60 2301 (71.5)
Cholesterol mg/dL 192.750.3
Pre-dialysis SBP 14724.9
Pre-dialysis DBP 79.514.5
Post-dialysis SBP 141.924.7
Post-dialysis DBP 75.314.1
Hematocrit % 30.56.1
Creatinine mg/dL 7.54.1
Calcium mg/dL 8.72.4
Phosphorous mg/dL 5.63.4
Calcium-phosphorous double product 47.516.2
Lowest quartile of calcium-phosphorous double
product (36, vs. highest, 56) 806 (25.1)
Serum bicarbonate mg/dL 22.36.8
Serum PTH pcg/L 307.9319.6
Daugirdas Kt/V 1.330.24
Temporary catheter 185 (5.5)
Goretex graft 816 (24.2)
Arteriovenous fistula 450 (13.3)
Hemodialysis 1675 (50.2)
Peritoneal dialysis 1662 (49.8)
Kt/V for peritoneal dialysis 2.161.06
ACE yes 740 (21.9)
Ramipril 23 (0.7)
Statin yes 310 (9.2)
CCB yes 1695 (50.2)
Non-dihyrdopyridine 439 (13.0)
Dihydropyridine 1371 (40.6)
Non-selective beta blockers yes 177 (5.2)
In column one, data are given as the number (% of total) or mean  one standard deviation of patients. Univariate odds ratios (with significance testing by chi
square) are the strength of the association of a disease or factor with time to hospitalization for acute coronary syndromes (ACS, ICD9 410.x or 411.x), with 1.0
being neutral. Abbreviations are: SBP, systolic blood pressure and DBP, diastolic blood pressure, both in mm Hg, obtained as the mean of three successive blood
pressures; CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; LVH, left ventricular hypertrophy; ECHO, echocardiography;
EKG, electrocardiogram; EPO, erythropoietin; CXR, chest radiographs; ACE, angiotensin-converting enzyme; CCB, calcium channel blockers. Comorbidities such
as coronary heart disease and congestive heart failure refer to a history of these conditions within ten years prior to the study period.
for all regression covariates. Stepwise logistic regression dependent variable was tested by Cox non-proportional
hazards regression analysis as previously described [5].was used to test the independent association of patient
factors with preexisting coronary heart disease, using the Time to ACS was defined as time from first dialysis
session until hospitalization for ACS, censored for death,same covariates as Cox regression above.
The association of ACS with mortality as a time- transplantation, loss to follow-up, or end of the study.
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Table 4. Cox regression of factors associated with hospitalized ACSTable 2. Event rates for acute coronary syndromes
Rate per 1000 P value Hazard ratio 95% CI
N person years
Age 71 (vs. 48) 0.04 2.34 1.05–5.23
Cholesterol 159–192 (vs. 159) 0.03 1.96 1.07–3.56Follow-up time years (mean  SD) 2.191.14
Ever transplanted 460 62.2 CHD 0.03 1.77 1.06–2.97
Male 0.03 1.72 1.06–2.81Died 1788 241.9
Hospitalized for ACS 211 28.6 Diabetes 0.047 1.61 1.01–2.58
Hemodialysis 108 28.8 Abbreviations are: ACS, acute coronary syndromes (ICD9 code 410.x, acute
Peritoneal dialysis 101 28.5 myocardial infarction, and code 411.x, unstable coronary syndromes); CHD,
Hospitalized for acute myocardial infarction 141 19.0 prior history of coronary heart disease.
ACS is acute coronary syndromes (ICD9 code 410.x or 411.x).
Unadjusted survival after ACS and for the entire co-
Table 3. Survival after acute coronary syndromes hort also is shown in Table 3. Survival was significantly
1 year 2 year 3 year worse after ACS compared to before ACS or in patients
who never experienced ACS in Cox non-proportional%
hazards regression analysis (adjusted hazard ratio forSurvival after ACSa 61 39 27
Survival after acute myocardial infarctionb 52 29 20 mortality 1.27, 95% CI 1.04–1.55, P  0.02). Cardiac-
Survival for entire cohort 83 66 49 specific mortality was higher also after ACS (adjusted
ACS is acute coronary syndromes (ICD9 code 410.x or 411.x). hazard ratio 1.34, 95% CI 1.02–1.77, P  0.04). In Cox
a Unadjusted cumulative percent survival, censored for receipt of renal trans-
regression analysis of all-cause mortality limited to pa-plant
b ICD9 code 410.x tients with ACS using the same covariates as above, the
only factors significantly associated with mortality were
a history of congestive heart failure (adjusted hazard
ratio, 1.58, 95% CI 1.07–2.33, P  0.02), and femaleRESULTS
gender (adjusted hazard ratio 1.49, 95% CI 1.02–2.17,A total of 4065 patients were included in the DMMS
P  0.04).Wave 2 cohort. Of these, 3621 patients had valid dates
Table 4 shows factors significant in multivariate analy-for starting dialysis in 1996. From this cohort, 3374 had
sis by Cox regression with incident ACS. Only five factorssufficient information to calculate follow-up times. Char-
were significant in multivariate analysis, all with positiveacteristics of the study population and univariate associa-
associations: older age, the second quartile of cholesteroltions with ACS are summarized in Table 1. The rate of
(vs. the lowest), prior history of coronary heart disease,ACS is shown in Table 2. Factors with significant nega-
male gender, and diabetes. Specifically, neither bloodtive univariate associations with ACS were female gen-
pressure, serum parathyroid hormone, dialysis modality,der, African American race, receipt of renal transplant
type of vascular access, or medication use was associated(at any time), and the highest quartile of serum parathy-
independently with ACS. There also were no significantroid hormone level. Factors with significant positive uni-
interactions between terms, specifically between medica-variate associations with ACS were older age, diabetes,
tions, laboratory data or dialysis modality in patientshistory of coronary heart disease and congestive heart
with preexisting coronary heart disease.failure, peripheral vascular disease, the second quartile
Because there was no association between cardiopro-of cholesterol (vs. the lowest), and use of aspirin and
tective medications and incident ACS, analysis also wasbeta blockers. There was no difference in the rate of ACS
performed of associations with preexisting coronary heartbetween patients who started on hemodialysis versus
disease (CHD). Among patients with preexisting CHDpatients who started on peritoneal dialysis. There were
prior to the study period (N  1091; Table 1), use of1788 total deaths in the cohort through 31 March 2000.
both angiotensin converting enzyme inhibitors (ACE,Mean follow-up was 2.19 1.14 years. The total mortal-
20.9 vs. 22.2%) and calcium channel blockers (CCB; 47.8ity rate for patients was 242/1000 person-years. Survival
vs. 51.3%) was less common than in patients who didafter ACS is shown in Table 3.
not have preexisting CHD (P not significant by 	2 forOf patients hospitalized for ACS, the most common
both comparisons). Use of beta blockers (24.2 vs. 16.7%)diagnosis was Non-Q-wave myocardial infarction (ICD9
and aspirin (32.5 vs. 11.4%) was more common in pa-410.71, 32%), followed by intermediate coronary syn-
tients with CHD than in those without (P  0.05 bydrome (ICD9 code 411.1, 30%), and anterior wall myo-
	2 for both comparisons). Statin use did not differ incardial infarction (20%). The most frequent secondary
univariate analysis (9.5 vs. 7.3%). Table 5 shows resultsdiagnoses were congestive heart failure (ICD9 code
of logistic regression of factors independently associated428.x, 14%), hypertensive heart disease (9%), and atrial
fibrillation (7%). with preexisting CHD. As shown, older age, male gen-
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Table 5. Logistic regression of factors associated with pre-existing tivariate analysis is rather striking. Older age, male gen-
coronary heart disease
der, diabetes, and prior history of coronary heart disease
Demographics P value Odds ratio 95% CI are well-established risk factors for coronary heart dis-
Age 71 (vs. 48) 0.01 4.43 2.91–6.48 ease in both the general population and among patients
Male 0.039 1.29 1.01–1.64 with ESRD, including recipients of renal transplants.
African American race 0.01 0.54 0.41–0.72
In contrast to previously published reports [3], theComorbidities
Peripheral vascular disease 0.01 3.14 2.17–4.17 present study did not find that calcium, phosphorous,
Congestive heart failure 0.01 5.12 4.04–6.48 calcium-phosphorous double product, or serum parathy-
Diabetes 0.01 1.65 1.29–2.11
roid hormone (PTH) level were independently associ-Medicationsa
Aspirin use 0.01 2.95 2.25–3.88 ated with ACS. This is actually not surprising, since the
Statin use 0.037 1.50 1.02–2.19 primary cause of ACS is rupture of unstable plaque with
Beta blocker use 0.01 2.11 1.60–2.80
subsequent thrombosis and spasm, not progressive vessel
Abbreviations are: ACS, acute coronary syndromes (ICD9 code 410.x, acute stenosis. Taylor et al have shown an inverse relationshipmyocardial infarction, and code 411.x, unstable coronary syndromes); CHD,
prior history of coronary heart disease. Among patients with pre-existing CHD between coronary artery calcification and the presence
prior to the study period (N  1091; from Table 1), use of both angiotensin- of such unstable plaques in the general population, al-converting enzyme inhibitors (ACE; 20.9% vs. 22.2%) and calcium channel
blockers (CCB, 47.8 vs. 51.3%) was less common than in patients who did not though this has not been studied in dialysis patients [20].
have pre-existing CHD (P not significant by chi square for both comparisons). Bonifacio et al also have shown that coronary arteryUse of beta blockers (24.2 vs. 16.7%) and aspirin (32.5 vs. 11.4%) was more
common in patients with CHD than in those without (P  0.05 by chi square calcification was associated with lower total cholesterol
for both comparisons). Statin use did not differ in univariate analysis (9.5% vs. and favorable outcomes after intervention in dialysis pa-7.3%) (see Results section).
tients [21]. Previous investigators have shown an inverse
relationship between serum PTH levels and survival [22].
However, chronic dialysis patients in the highest quartile
der, and diabetes, as well as history of congestive heart of calcium-phosphorous double product were at in-
failure and peripheral vascular disease were associated creased risk of all-cause mortality, independent of PTH
with CHD. Among medications, aspirin, beta-blockers, level [23]. Neither study assessed specific causes of death.
and statins were associated with CHD. It is possible that elevated calcium-phosphorous level has
a stronger association with chronic than acute coronary
syndromes, is a marker of poor nutritional compliance
DISCUSSION or infectious mortality, or that management has changed
The incidence of ACS reported in the present study significantly in more recent years, since previous studies
was 29/1000 person-years, in comparison to a rate of 18/ analyzed earlier cohorts.
1000 person-years in diabetic patients listed for renal Blood pressure has not consistently been associated
transplantation who did not receive transplants [5]. This with ACS in studies of either the general population or
is not unexpected since patients are carefully screened in patients with ESRD [7]. Recent trials have shown that
prior to listing for renal transplant, and thus the rate of specific classes of medications (angiotensin converting
ACS for all dialysis patients would be expected to be enzyme inhibitors [24] and angiotensin receptor blockers
higher. Also in agreement with previous studies, the all- [25]) reduce cardiovascular events more than other med-
cause mortality after ACS was significantly higher in ications at similar levels of blood pressure reduction.
comparison with the cohort of all dialysis patients [2]. Blood pressure is closely linked to dry weight and diet
Herzog et al, in analysis of a cohort of dialysis patients in dialysis patients [26], and although the mean of three
from 1977 to 1995, reported that mortality after myocar- readings was used, we could not assess changes in blood
dial infarction in dialysis patients was 59% at one year, pressure over time.
73% at two years, and 89% at three years, although mor- We did not find any significant association between
tality was significantly better in the more recent years medication use and the incidence of ACS. This is quite
of the study [2]. Our study suggested improvement over possibly due to the striking under-utilization of these
time but still substantial mortality (Table 3). A higher medications in this at-risk population. Although use of
mortality rate for women than men after myocardial cardioprotective medications was more common in pa-
infarction has been shown in the general population, as tients with CHD, only a minority of patients with pre-
in this study. Canto et al showed that gender differences existing CHD were prescribed cardioprotective medica-
did not persist after differences in the utilization of both tions. Although statin use was more common in patients
pharmacologic treatments administered within the first with CHD, this class of medications was still used in
24 hours (which the present study could not measure) fewer than 10% patients with preexisting CHD who had
and accounted for the invasive cardiac procedures [19]. been under nephrology care for at least two months.
Although many factors were significant in univariate This is remarkable considering the recent findings of im-
proved survival in dialysis patients with the use of statinsanalysis, the relative paucity of factors significant in mul-
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States: A cross-sectional study. J Am Soc Nephrol 12:1516–1523,[12]. Another notable finding was that the use of ACE
2001
inhibitors, which have known benefits on CHD in the 4. Rigatto C, Parfrey P, Foley R, et al: Congestive heart failure in
general population and in patients with renal insuffi- renal transplant recipients: Risk factors, outcomes, and relationship
with ischemic heart disease. J Am Soc Nephrol 13:1084–1090, 2002ciency [24], and calcium channel blockers, which have
5. Hypolite IO, Bucci JR, Hshieh PB, et al: Acute coronary syn-recently been shown to provide a survival advantage in dromes after renal transplantation in patients with end stage renal
dialysis patients [27], was actually lower in patients with disease resulting from diabetes. Am J Transplant 2:274–281, 2002
6. Ganesh SK, Stack AG, Levin NW, et al: Association of elevatedCHD. Our findings also may be a result of the narrowed
serum PO(4), Ca x PO(4) product, and parathyroid hormone withscope of our study and its relatively short follow-up. cardiac mortality risk in chronic hemodialysis patients. J Am Soc
Because the present study was observational and not Nephrol 12:2131–2138, 2001
7. Piros S, Karlehagen S, Lappas G, Wilhelmsen L: Risk factorsrandomized, our findings could still be skewed despite
for myocardial infarction among Swedish railway engine driversadjustment. It is a random sample of all hemodialysis during 10 years follow-up. J Cardiovasc Risk 7:395–400, 2000
patients, not the total population, although the perito- 8. US Renal Data System: Researcher’s Guide to the USRDS Data-
base. Bethesda, The National Institutes of Health, National Insti-neal dialysis population was almost fully captured. Infor-
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2001could not follow changes in blood pressure, laboratory 10. Burke AP, Farb A, Malcom GT, et al: Coronary risk factors
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12. Seliger SL, Weiss NS, Gillen DL, et al: HMG-CoA reductaseif not verified by autopsy, are also of questionable valid-
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did not have access to inflammatory markers, such as 13. Wolfe RA, Ashby VB, Milford EL, et al: Comparison of mortality
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tion, and recipients of a first cadaveric transplant. N Engl J Medmarker with coronary heart disease in dialysis patients
341:1725–1730, 1999
remains controversial [29, 30]. 14. Garg PP, Diener-West M, Powe NR: Reducing racial disparities
in transplant activation: Whom should we target? Am J Kidney DisIn summary, the present observational, non-random-
37:921–931, 2001ized study confirms the high incidence and mortality of
15. Keshaviah P, Collins AJ, Ma JZ, et al: Survival comparison
ACS in chronic dialysis patients. In addition, traditional between hemodialysis and peritoneal dialysis based on matched
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